Clinical relevance of pre- and coseasonal sublingual immunotherapy with a 300 index of reactivity 5-grass SLIT tablet in allergic rhinoconjunctivitis.

"CONFLICT OF INTEREST STATEMENT O Pfaar reports grants and/or personal fees from ALK‐Abelló, Allergopharma, Stallergenes Greer, HAL Allergy Holding B.V./HAL Allergie GmbH, Bencard Allergie GmbH/Allergy Therapeutics, Lofarma, ASIT Biotech Tools S.A., Laboratorios LETI/LETI Pharma, GlaxoSmithKline, ROXALL Medizin, Novartis, Sanofi‐Aventis und Sanofi‐Genzyme, Med Update Europe GmbH, streamedup! GmbH, Pohl‐Boskamp, Inmunotek S.L., John Wiley and Sons, AS, Paul‐Martini‐Stiftung (PMS), Regeneron Pharmaceuticals Inc., RG Aerztefortbildung, Institut für Disease Management, Springer GmbH, AstraZeneca, IQVIA Commercial, Ingress Health, Wort&Bild Verlag, Verlag ME, Procter&Gamble, ALTAMIRA, Meinhardt Congress GmbH, Deutsche Forschungsgemeinschaft, Thieme, Deutsche AllergieLiga e.V., AeDA, Alfried‐Krupp Krankenhaus, Red Maple Trials Inc., Königlich Dänisches Generalkonsulat, Medizinische Hochschule Hannover, ECM Expro&Conference Management, Technische Universität Dresden, Lilly, Paul Ehrlich Institut, all outside the submitted work and within the last 36 months; and he is member of EAACI Excom, member of ext. Board of directors DGAKI; coordinator, main‐ or co‐author of different position papers and guidelines in rhinology, allergology and allergen‐immunotherapy. U. Wahn reports personal fees from ALK‐Abelló, personal fees from Berlin‐Chemie, Novartis, Stallergenes Greer and Viatris, outside the submitted work. G.W. Canonica has nothing to disclose for this paper. F. Bahbah is a former employee of Stallergenes Greer and reports personal fees and non‐financial support from Stallergenes Greer during her time with the company. P. Devillier reports personal fees and non‐financial supports from ALK‐ Abelló, Astra Zeneca, Chiesi, GlaxoSmithKline, IQVIA, Menarini, Procter & Gamble, Stallergenes Greer and Viatris."

"Open Access funding enabled and organized by Projekt DEAL."